| Value | ₹120.8 Cr |
|---|---|
| Order from | HarmeeCare Pharmaceuticals |
BSE filing, NSE: KILITCH. Summary written from the filing by ALFA Finder's alert engine.
Kilitch Drugs(I) Ltd: key numbers
- Share price
- ₹201.32
- Market cap
- ₹703.9 Cr
- Revenue (annual)
- ₹235.5 Cr
- Net profit (annual)
- ₹30.17 Cr
- P/E (TTM)
- 23.4×Sector 45.9×
- Promoter holding
- 63.77%+0.00% QoQ
- FII holding
- 0.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kilitch Drugs(I) Ltd
All →Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs' EGM notice seeks shareholder approval for selling its Ethiopian material subsidiary and converting subsidiary debt into equity. It also proposes two independent director appointments.
Kilitch Drugs(I) Merger & Restructuring Worth ₹131.6 Cr
Kilitch Drugs will divest its entire Ethiopian subsidiary stake to HarmeeCare for US$14 million (~₹131.6 Crore). Proceeds will fund debt repayment and Pen plant expansion.
- Value
- ₹131.6 Cr
Kilitch Drugs(I) Management Change
Kilitch Drugs' Non-Executive Independent Director Mr. Venkita Subramanian Rajan resigned effective 21 Oct 2026. He also stepped down from the Audit, NCR, and SRC Committees citing personal commitments.
Kilitch Drugs(I) Other Announcement
Kilitch Drugs (India) Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026.
Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs (India) held its 34th Annual General Meeting on August 27, 2026, transacting four business resolutions including financial statement approval and director re-appointment.
Kilitch Drugs(I) Other Announcement
Kilitch Drugs filed its Monitoring Agency Report for the quarter ended June 30, 2026, concerning its Rights Issue proceeds of Rs. 49.92 Crore.
- Value
- ₹49.92 Cr
Other merger & restructuring announcements
All →Sapphire Foods India Merger & Restructuring
Sapphire Foods received CCI approval under Section 31(1) for its proposed merger into Devyani International under a Scheme of Arrangement. The detailed CCI order is still awaited.
Aditya Ispat Merger & Restructuring
Aditya Ispat's steel slump sale to related party Jai Bapji Ispat now completes by 31 December 2026. Delay stems from pre-closing actions under the business transfer agreement.
Vahh Chemicals Merger & Restructuring Worth ₹0.1 Cr
VAHH Chemicals will incorporate Vedant Nutrition Limited as a wholly owned nutraceutical subsidiary with Rs 0.10 Crore cash. Incorporation is tentatively dated November 5, 2026.
- Value
- ₹0.10 Cr
Tata Communications Merger & Restructuring
Tata Communications transferred its 100% Kaleyra, Inc. stake to TCNL and Kaleyra, Inc. merged into Kaleyra US Inc. Intra-group restructuring; ultimate ownership unchanged.
Greenleaf Envirotech Merger & Restructuring Worth ₹16.8 Cr
Greenleaf Envirotech approved an AOP joint venture with Krishna Construction (Gujarat) LLP to execute a Rs.16.80 Crore Jal Nigam sewage project. Greenleaf will act as lead partner.
- Value
- ₹16.80 Cr
Solarworld Energy Solutions Merger & Restructuring Worth ₹26.82 Cr
Solarworld paid Rs 26.82 Crore on October 30, 2026 as the first tranche of its equity subscription in Rays Green Energy Manufacturing, a 50-50 joint venture. Rays Green allotted 12,600 shares on October 31, 2026, and the balance of up to Rs 73.18 Crore is still due.
- Value
- ₹26.82 Cr